In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach

In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach

Breast cancer remains one of the most prevalent and lethal malignancies in women, particularly the estrogen receptor-positive (ER+) subtype, which accounts for approximately 70% of cases. Traditional endocrine therapies, including aromatase inhibitors, selective estrogen receptor degraders/antagonis...

Full description

Saved in:
Bibliographic Details
Main Authors: Gabriele La Monica, Federica Alamia, Alessia Bono, Francesco Mingoia, Annamaria Martorana, Antonino Lauria
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Molecules
Subjects:
estrogen receptor (ER)
Hsp90 inhibition
endocrine resistance
multitarget drug design
DRUDIT
NCI database
Online Access:https://www.mdpi.com/1420-3049/29/24/6040
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items